FRBN

NASDAQ

Forbion European Acquisition Corp.

SectorFinanceIndustryBlank ChecksIPO2022

News25/Ratings0

Forbion European Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to identify opportunities in the life sciences industry in Europe. The company was incorporated in 2021 and is based in Wilmington, Delaware.

Latest news

25 items

799d13D/G
SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
799d13D/G
SEC Form SC 13G filed by Forbion European Acquisition Corp.
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
805d13D/G
SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
825d13D/G
SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
892dSEC
SEC Form 15-12G filed by Forbion European Acquisition Corp.
15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)
904dSEC
Forbion European Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
904d13D/G
SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)
SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)
905dINSIDER
Forbion Growth Sponsor Feac I B.V. returned 3,373,496 units of Class A Ordinary Shares to the company (SEC Form 4)
4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
905dINSIDER
Forbion Growth Sponsor Feac I B.V. converted options into 1,373,496 units of Class A Ordinary Shares (SEC Form 4)
4 - Forbion European Acquisition Corp. (0001874495) (Issuer)
905dINSIDER
New insider Forbion Growth Sponsor Feac I B.V. claimed ownership of 2,000,000 units of Class A Ordinary Shares (SEC Form 3) (Amendment)
3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)
905dSEC
SEC Form 25-NSE filed by Forbion European Acquisition Corp.
25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)
906dNEWS
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Eargo, Inc. (NASDAQ:EAR) shares climbed 50.4% to $2.5274 after the company announced it will be taken private by Patient Square Capital. VYNE Therapeutics Inc. (NASDAQ:VYNE) gained 39.9% to $3.1399 after the company announced a private placement of $88 million and data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares gained 27.9% to $1.3042 after falling more than 12% on Friday. HeartCore Enterprises, Inc. (NASDAQ:HTCR)
909dSEC
SEC Form 10-Q filed by Forbion European Acquisition Corp.
10-Q - Forbion European Acquisition Corp. (0001874495) (Filer)
911dNEWS
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ:ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. Nuvve Holding Corp. (NASDAQ:NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million shares of common stock at a price to the public of $0.14 per share. BIO-key International, Inc. (NASDAQ:BKYI) surged 57% to $0.30. BIO-key International reported results for its third quarter ended Sept. 30, 2023. ReShape Lifesciences Inc. (NASDAQ:RSLS) gained 44.7% to $0.2976 after gaining over 6% on Tuesday. ReShape Lifesciences recently announced p
912dSEC
SEC Form 8-K filed by Forbion European Acquisition Corp.
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
919dSEC
SEC Form DEFA14A filed by Forbion European Acquisition Corp.
DEFA14A - Forbion European Acquisition Corp. (0001874495) (Filer)
926d13D/G
SEC Form SC 13G filed by Forbion European Acquisition Corp.
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
930d13D/G
SEC Form SC 13G filed by Forbion European Acquisition Corp.
SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)
937dSEC
SEC Form DEFM14A filed by Forbion European Acquisition Corp.
DEFM14A - Forbion European Acquisition Corp. (0001874495) (Filer)
951dSEC
Forbion European Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
953dSEC
SEC Form 425 filed by Forbion European Acquisition Corp.
425 - Forbion European Acquisition Corp. (0001874495) (Subject)
953dSEC
Forbion European Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - Forbion European Acquisition Corp. (0001874495) (Filer)
959dPR
enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer
BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clinical development of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the development strategy for enGene's therapeutic pipeline of tissue-targeted non-viral gene therapies.
986dSEC
SEC Form 10-Q filed by Forbion European Acquisition Corp.
10-Q - Forbion European Acquisition Corp. (0001874495) (Filer)
1000dSEC
SEC Form 425 filed by Forbion European Acquisition Corp.
425 - Forbion European Acquisition Corp. (0001874495) (Subject)